Vésale Bioscience wins R&D grant
Phage therapy specialist Vésale Bioscience gas bageds €1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2169 entries already.
Entries by Thomas Gabrielczyk
It’s on: the race for sustainable packaging
A decade ago, the news about the Great Pacific Garbage Patch went viral. Since then, a multitude of startups proliferated on a mission to create ecological alternatives to the ubiquitous fossil-based plastics. At ECBF, we are closely monitoring the emerging materials for packaging applications, by far the main use case of plastics.
Abionyx Pharma announces success in fighting sepsis-triggered AKI
Abionyx Pharma SA has announced positive data from Phase IIa testing of iCER-001, a recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI)
BioNTech bags Instadeep for £562m
BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
At the interface of AI, healthcare, and data science
The AI Health Innovation Cluster is bringing together leading scientists at the interface
of artificial intelligence (AI), healthcare, and data science. The goal is to combine and further develop the outstanding research networks and infrastructures in modern health data sciences that have emerged in the Rhine-Neckar region in Germany in recent years.
Roche withdraws checkpoint blocker from the market
Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.
Lessons learned in the face of new health challenges
SARS-COV-2 exposed our vulnerability and strategic weakness at European level, in terms of biotechnological manufacturing capacity.
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
Hummingbird and Synaffix in $150m ADC deal
Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
Ethris inks €15m deal with Indian Ciplas
Cipla EU Ltd is going to make an equity investment of €15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs.